Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.37 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25584062 | 0.98 | LPAR3 (0.40) | LPAR3LPAR2LPAR1CYP2D6CYP1A2 | |
| SCHEMBL26688599 | 0.92 | PLA2G2A (0.37) | LPAR3LPAR2LPAR1CYP2D6CYP1A2 | |
| SCHEMBL26334857 | 0.88 | CYP2D6 (0.39) | LPAR3LPAR2LPAR1CYP2D6CYP1A2 | |
| SCHEMBL26334849 | 0.86 | CYP2D6 (0.42) | LPAR3LPAR2LPAR1CYP2D6CYP1A2 | |
| SCHEMBL26334858 | 0.86 | CYP2D6 (0.42) | LPAR3LPAR2LPAR1CYP2D6CYP1A2 | |
| SCHEMBL26334850 | 0.86 | CYP2D6 (0.42) | LPAR3LPAR2LPAR1CYP2D6CYP1A2 | |
| SCHEMBL22193586 | 0.84 | LPAR3 (0.40) | LPAR3LPAR2LPAR1CYP2D6CYP1A2 | |
| SCHEMBL16417850 | 0.82 | LPAR3 (0.47) | LPAR3LPAR2LPAR1CYP2D6CYP1A2 | |
| SCHEMBL14816068 | 0.81 | BTN3A1 (0.44) | LPAR3LPAR2LPAR1CYP2D6CYP1A2 | |
| SCHEMBL12091539 | 0.81 | SAT1 (0.44) | LPAR3LPAR2LPAR1CYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240026421-A1 | METHODS FOR CAPTURING LONG POLYNUCLEOTIDES FOR SEQUENCING SPECIFIC GENOMIC REGIONS | GENERATION BIOTECH, LLC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240026421-A1 | METHODS FOR CAPTURING LONG POLYNUCLEOTIDES FOR SEQUENCING SPECIFIC GENOMIC REGIONS | GENERATION BIOTECH, LLC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11821023-B2 | Method for capturing long polynucleotides for sequencing specific gnomic regions | GENERATION BIOTECH, LLC (US) | 2023-11-21 | — | — | US | disclosed |
| US-11821023-B2 | Method for capturing long polynucleotides for sequencing specific gnomic regions | GENERATION BIOTECH, LLC (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230366885-A1 | DNA CONSTRUCTS, RECOMBINANT CELLS COMPRISING THEREOF, BACTERIAL PROBES, METHODS FOR THEIR PREPARATION, AND METHOD OF USING THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-11-16 | — | — | US | disclosed |
| US-11639929-B2 | Universal histidine-tag binding compounds and methods of use thereof as fluorescent probes and sensors | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-05-02 | — | — | US | disclosed |
| US-20180057870-A1 | TAGGED NUCLEOTIDES USEFUL FOR NANOPORE DETECTION | Roche Sequencing Solutions, Inc. | 2018-03-01 | — | — | US | disclosed |
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | BRADSHAW CURT W (US) | 2017-04-27 | — | — | US | disclosed |
| WO-2015188197-A2 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | SOLSTICE BIOLOGICS, LTD. (IE) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11639929-B2 | Universal histidine-tag binding compounds and methods of use thereof as fluorescent probes and sensors | HCLS1, PHF6, PHPT1 | LPAR3 4564/4885LPAR2 4740/4885LPAR1 4548/4885 |
| US-20180057870-A1 | TAGGED NUCLEOTIDES USEFUL FOR NANOPORE DETECTION | PHAX, POLRMT, POLN | LPAR3 3474/4885LPAR2 3499/4885LPAR1 3376/4885 |
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | HNRNPC, RNASE1, NSUN3 | LPAR3 3097/4885LPAR2 3879/4885LPAR1 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.